These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

608 related items for PubMed ID: 10640731

  • 1. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit antigen-induced apoptosis of mature T lymphocytes by inhibiting Fas ligand expression.
    Delgado M, Ganea D.
    J Immunol; 2000 Feb 01; 164(3):1200-10. PubMed ID: 10640731
    [Abstract] [Full Text] [Related]

  • 2. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit expression of Fas ligand in activated T lymphocytes by regulating c-Myc, NF-kappa B, NF-AT, and early growth factors 2/3.
    Delgado M, Ganea D.
    J Immunol; 2001 Jan 15; 166(2):1028-40. PubMed ID: 11145682
    [Abstract] [Full Text] [Related]

  • 3. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit T cell-mediated cytotoxicity by inhibiting Fas ligand expression.
    Delgado M, Ganea D.
    J Immunol; 2000 Jul 01; 165(1):114-23. PubMed ID: 10861043
    [Abstract] [Full Text] [Related]

  • 4. VIP and PACAP inhibit activation induced apoptosis in T lymphocytes.
    Delgado M, Ganea D.
    Ann N Y Acad Sci; 2000 Jul 01; 921():55-67. PubMed ID: 11193880
    [Abstract] [Full Text] [Related]

  • 5. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide stimulate the induction of Th2 responses by up-regulating B7.2 expression.
    Delgado M, Leceta J, Gomariz RP, Ganea D.
    J Immunol; 1999 Oct 01; 163(7):3629-35. PubMed ID: 10490956
    [Abstract] [Full Text] [Related]

  • 6. VIP/PACAP oppositely affects immature and mature dendritic cell expression of CD80/CD86 and the stimulatory activity for CD4(+) T cells.
    Delgado M, Reduta A, Sharma V, Ganea D.
    J Leukoc Biol; 2004 Jun 01; 75(6):1122-30. PubMed ID: 15020654
    [Abstract] [Full Text] [Related]

  • 7. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) as modulators of both innate and adaptive immunity.
    Ganea D, Delgado M.
    Crit Rev Oral Biol Med; 2002 Jun 01; 13(3):229-37. PubMed ID: 12090463
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. VIP1 and VIP2 receptors but not PVR1 mediate the effect of VIP/PACAP on cytokine production in T lymphocytes.
    Jiang X, Wang HY, Yu J, Ganea D.
    Ann N Y Acad Sci; 1998 Dec 11; 865():397-407. PubMed ID: 9928038
    [Abstract] [Full Text] [Related]

  • 10. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
    Akesson L, Ahrén B, Edgren G, Degerman E.
    Endocrinology; 2005 Feb 11; 146(2):744-50. PubMed ID: 15514088
    [Abstract] [Full Text] [Related]

  • 11. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies.
    Delgado M, Munoz-Elias EJ, Gomariz RP, Ganea D.
    J Immunol; 1999 Feb 01; 162(3):1707-16. PubMed ID: 9973433
    [Abstract] [Full Text] [Related]

  • 12. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.
    Alexandre D, Anouar Y, Jegou S, Fournier A, Vaudry H.
    Endocrinology; 1999 Mar 01; 140(3):1285-93. PubMed ID: 10067855
    [Abstract] [Full Text] [Related]

  • 13. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory factor 1 activation.
    Delgado M, Munoz-Elias EJ, Gomariz RP, Ganea D.
    J Immunol; 1999 Apr 15; 162(8):4685-96. PubMed ID: 10202009
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of IFN-gamma-induced janus kinase-1-STAT1 activation in macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide.
    Delgado M, Ganea D.
    J Immunol; 2000 Sep 15; 165(6):3051-7. PubMed ID: 10975815
    [Abstract] [Full Text] [Related]

  • 15. Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary.
    Barberi M, Muciaccia B, Morelli MB, Stefanini M, Cecconi S, Canipari R.
    Reproduction; 2007 Aug 15; 134(2):281-92. PubMed ID: 17660238
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of endotoxin-induced macrophage chemokine production by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in vitro and in vivo.
    Delgado M, Ganea D.
    J Immunol; 2001 Jul 15; 167(2):966-75. PubMed ID: 11441105
    [Abstract] [Full Text] [Related]

  • 17. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide-38 inhibit IL-10 production in murine T lymphocytes.
    Martinez C, Delgado M, Gomariz RP, Ganea D.
    J Immunol; 1996 Jun 01; 156(11):4128-36. PubMed ID: 8666779
    [Abstract] [Full Text] [Related]

  • 18. VIP and PACAP enhance the in vivo generation of memory TH2 cells by inhibiting peripheral deletion of antigen-specific effectors.
    Delgado M, Ganea D.
    Arch Physiol Biochem; 2001 Oct 01; 109(4):372-6. PubMed ID: 11935376
    [Abstract] [Full Text] [Related]

  • 19. Vasoactive intestinal peptide (VIP) inhibits TGF-beta1 production in murine macrophages.
    Sun W, Tadmori I, Yang L, Delgado M, Ganea D.
    J Neuroimmunol; 2000 Jul 10; 107(1):88-99. PubMed ID: 10808055
    [Abstract] [Full Text] [Related]

  • 20. Shedding of membrane-bound CD14 from lipopolysaccharide-stimulated macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide.
    Delgado M, Leceta J, Abad C, Martinez C, Ganea D, Gomariz RP.
    J Neuroimmunol; 1999 Sep 01; 99(1):61-71. PubMed ID: 10496178
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.